why choose us

First received: February 02, 2023

Clinical Trial: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Neoplasms, Rectal

Study Type: INTERVENTIONAL


Official Title: A Phase 2, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer

Brief Summary: The purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment.Participants who achieve complete clinical response (cCR) following dostarlimab treatment will undergo non-operative management (NOM), including close surveillance for recurrent disease.The goal of the study is to determine if Dostarlimab therapy alone is an effective treatment that…

Read more